Market open
Janux Therapeutics/$JANX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Ticker
$JANX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
91
ISIN
US47103J1051
Website
JANX Metrics
BasicAdvanced
$1.3B
-
-$1.37
3.24
-
Price and volume
Market cap
$1.3B
Beta
3.24
52-week high
$64.87
52-week low
$22.48
Average daily volume
1.1M
Financial strength
Current ratio
58.47
Quick ratio
58.264
Long term debt to equity
2.054
Total debt to equity
2.233
Management effectiveness
Return on assets (TTM)
-8.16%
Return on equity (TTM)
-9.32%
Valuation
Price to revenue (TTM)
137.952
Price to book
1.32
Price to tangible book (TTM)
1.32
Price to free cash flow (TTM)
-27.677
Growth
Revenue change (TTM)
28.12%
Earnings per share change (TTM)
12.58%
3-year revenue growth (CAGR)
24.43%
3-year earnings per share growth (CAGR)
1.54%
What the Analysts think about JANX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
JANX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
JANX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
JANX News
AllArticlesVideos
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
Business Wire·3 hours ago
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
Business Wire·1 week ago
Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Janux Therapeutics stock?
Janux Therapeutics (JANX) has a market cap of $1.3B as of May 15, 2025.
What is the P/E ratio for Janux Therapeutics stock?
The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of May 15, 2025.
Does Janux Therapeutics stock pay dividends?
No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Janux Therapeutics dividend payment date?
Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Janux Therapeutics?
Janux Therapeutics (JANX) has a beta rating of 3.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.